Investigators elucidated the molecular hallmarks and therapeutically actionable features of patients with resistance to CDK4/6 inhibitors.
[Molecular Cancer]
Home Newsletters Mammary Cell News S6K1 Amplification Confers Innate Resistance to CDK4/6 Inhibitors through Activating C-myc Pathway...
